Calcitonin Gene-Related Peptide (CGRP) in patients with migraine and endometriosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020744

Enrollment

120

Registered

2020-02-12

Start date

2019-01-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G43.0 N80.9

Interventions

Group 1: Patients with migraine and endometriosis Group 2: Patients with migraine without endometriosis Group 3: Patients with endometriosis without migraine Group 4: Healthy controls

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: - diagnosed migraine according to the International Headache Society (IHS) criteria - laparoscopically diagnosed endometriosis

Exclusion criteria

Exclusion criteria: - age 60 years; - other known headache disorders - current intake of a migraine prophylactic medication - unregular or absent menstrual cycle (e.g. pregnancy, post-menopausal, hormonal contraception, sterilisation).

Design outcomes

Primary

Measure	Time frame
Difference in the CGRP plasma concentrations between d2 and d15 of menstrual cycle in patients with migraine and endometriosis (compared to patients with migraine only, endometriosis only, and healthy controls)	—

Secondary

Measure	Time frame
CGRP plasma concentrations at d2 and d15 of menstrual cycle in patients with migraine and endometriosis (compared with patients with migraine only, endometriosis only, and healthy controls)	—

Countries

Germany

Contacts

Public ContactBianca Raffaelli

Charité - Universitätsmedizin BerlinKlinik für Neurologie

bianca.raffaelli@charite.de+49 (0)30 450 660168

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026